Table III.
Univariate regression analysis results for overall mortality
| Factor | Hazard Ratio | 95% CI | p-value |
|---|---|---|---|
| Age* | Older, more failure | --- | .65 |
| Age < 60 | 1 | --- | .87 |
| Age ≥ 60 | 1.11 | 0.34–3.64 | .87 |
| Stage III† | 1 | --- | --- |
| Stage IV | 1.42 | 0.18–10.94 | .74 |
| PS 0–1 | 1 | --- | --- |
| PS 2–3 | 1.99 | 0.26–15.45 | .51 |
| Normal LDH‡ | 1 | --- | --- |
| High LDH | 1 | .0005 | |
| ENS 0–1 | 1 | --- | --- |
| ENS 2–3 | 2.02 | 0.60–6.78 | .26 |
| No B Symptoms | 1 | --- | --- |
| B Symptoms | 1.96 | 0.66–5.85 | .23 |
| IPI 0–1 | 1 | --- | --- |
| IPI 2–3 | 4.83 | 1.07–21.85 | .04 |
| IPI 4–5 | 0 | --- | 23 |
| Female | 1 | --- | --- |
| Male | 1.50 | 0.33–6.77 | .60 |
| No Splenomegaly | 1 | --- | --- |
| Splenomegaly | 3.06 | 0.84–11.14 | .09 |
| No BM Involvement | 1 | --- | --- |
| BM Involvement | 0.92 | 0.20–4.19 | .92 |
| No GI Involvement | 1 | --- | --- |
| GI Involvement | 1.24 | 0.34–4.53 | .75 |
| Hb < 12 | 1 | --- | --- |
| Hb ≥ 12 | 0.49 | 0.15–1.60 | .23 |
| Number of Cycles of Induction Chemo* | Higher, less failure | --- | .15 |
| No Rituximab in Induction | 1 | --- | --- |
| Rituximab in Induction | 0.33 | 0.11–1.00 | .05 |
| 0–1 pre-ASCT Chemo | 1 | --- | --- |
| ≥2 Chemo | 8.38 | 1.85–37.96 | .006 |
| CR to Induction | 1 | --- | --- |
| No CR to Induction | 5.65 | 1.25–25.64 | .02 |
| CR1 at ASCT | 1 | --- | --- |
| PR1 at ASCT | 2.93 | 0.27–32.41 | .38 |
| Neither CR1 nor PR1 at ASCT | 10.85 | 1.38–85.11 | .02 |
| No Post-ASCT | 1 | --- | --- |
| Rituximab Post-ASCT Rituximab | 0.13 | 0.02–1.03 | .05 |
| Group 1 (HyperCVAD ) | 1 | --- | --- |
| Group 2 (CHOP) | 2.28 | 0.21–25.26 | .50 |
| Group 3 (relapsed/refractory) | 9.76 | 1.24–76.98 | .03 |
*
Age, number of cycles, and number of pre-ASCT chemo regimens modeled as a continuous linear variable
†
No patients with Stage II disease, only 1 patient with Stage I disease
‡
Fourteen patients missing data, 6 (43%) have died